Product information and disease descriptionProduct descriptionProduct information
Effect of Cretostimogene grenadenorepvec on quality measures
1 evidence topic · 1 source
Quality measure for intravesical BCG in newly diagnosed non-muscle-invasive bladder cancer
| Field | Quoted record |
|---|---|
| Title | “Intravesical Bacillus-Calmette-Guerin for Non-Muscle Invasive Bladder Cancer” |
| MIPS Quality ID | “481” |
| Measure steward | “Oregon Urology” |
| Description | “Percentage of patients initially diagnosed with non-muscle invasive bladder cancer and who received intravesical Bacillus-Calmette-Guerin (BCG) within 6 months of bladder cancer staging” |
| Measure type | “Process” |
| Denominator exclusion | “Patients who undergo cystectomy, chemotherapy or radiation within 6 months of Bladder Cancer Staging” |
| Denominator exception | “Unavailability of BCG within 6 months after Bladder Cancer Staging” |
Product-specific effect on quality measures
No evidence found.